Browse SEZ6L

Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum membrane Single-pass type I membrane protein
Domain PF00431 CUB domain
PF00084 Sushi repeat (SCR repeat)
Function

May contribute to specialized endoplasmic reticulum functions in neurons.

> Gene Ontology
 
Biological Process GO:0007626 locomotory behavior
GO:0008344 adult locomotory behavior
GO:0021549 cerebellum development
GO:0021680 cerebellar Purkinje cell layer development
GO:0021695 cerebellar cortex development
GO:0021700 developmental maturation
GO:0022037 metencephalon development
GO:0030534 adult behavior
GO:0030902 hindbrain development
GO:0044708 single-organism behavior
GO:0050808 synapse organization
GO:0060074 synapse maturation
GO:0070528 protein kinase C signaling
GO:0090036 regulation of protein kinase C signaling
Molecular Function -
Cellular Component GO:0043025 neuronal cell body
GO:0044297 cell body
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SEZ6L and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SEZ6L in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SEZ6L in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2430.672
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2110.843
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.8150.523
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0460.953
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2190.876
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5830.659
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0450.91
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.1220.84
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.040.901
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SEZ6L in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277322.24.118.10.011
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275922.25.117.10.0245
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.211.12.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.814.34.51
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SEZ6L. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SEZ6L. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SEZ6L.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SEZ6L. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SEZ6L expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SEZ6L and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSEZ6L
Nameseizure related 6 homolog (mouse)-like
Aliases seizure related gene 6 (mouse)-like; seizure related gene 6-like; Seizure 6-like protein
Chromosomal Location22q12.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SEZ6L collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.